Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in ...

ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatmentChildren ages ...
Medscape

Extension Study Supports Roflumilast’s Safety, Efficacy for Atopic Dermatitis in Young Children

Roflumilast cream 0.05% provides durable efficacy and is well-tolerated for up to 56 weeks in children aged 2-5 years with mild-to-moderate atopic dermatitis, a study finds.
Healio

Zoryve cream 0.15% improves atopic dermatitis across diverse skin types

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. More than a quarter of patients achieved a clear or ...
Healio

Tapinarof cream improves sleep in pediatric patients with atopic dermatitis

Among patients aged 2 to 17 years with moderate to severe atopic dermatitis, tapinarof cream 1% significantly improved sleep, ...
Business Insider

Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program

Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index (EASI) in just 4 weeks 85% achieved ...
Monthly Prescribing Reference

Zoryve Cream 0.15% for Atopic Dermatitis Now Available

Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...
Medical Dialogues

Once-Daily Roflumilast Cream Delivers Lasting Benefits in Atopic Dermatitis: Study Shows

USA: A subgroup analysis published in The Journal of Allergy and Clinical Immunology reports that roflumilast cream may provide sustained improvement in patients with atopic dermatitis, including ...
Everyday Health on MSN

How to manage atopic dermatitis during menopause

Declining estrogen levels can lead to skin barrier dysfunction and eczema flares during menopause. Learn about skin-care adjustments, medical treatments, and the role of menopausal hormone therapy.
Business Wire

Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic ...

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, ...
Seeking Alpha

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age

Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease control Rapid and significant improvements in disease clearance with ZORYVE cream ...
Seeking Alpha

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere ...
Monthly Prescribing Reference

Zoryve Cream 0.15% Approved for Atopic Dermatitis

Credit: Arcutis. The approval was supported by data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials. The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.15% for ...